ClinicalTrials.gg
RecruitingNCT07515508MIRACLEUpdated Jul 29, 2026

Multimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE

An observational study in Cardiogenic Shock and Acute Heart Failure (AHF), sponsored by University Heart Center Freiburg - Bad Krozingen. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by University Heart Center Freiburg - Bad Krozingen · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.

Planned enrollment
5th of 14
600 · median 138
Started
2024
with 2 others
Observational
14 of 36
8 open now
Primary completion
2027-07
later than 4 of 12 live
Registered
33rd of 36
by date

Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 4 of the 12 other live ones, and was the 33rd registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Shock, Cardiogenic with a site in Germany, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether information collected during routine hospital care, together with blood and urine samples, can help doctors better identify different types of cardiogenic shock and better predict outcomes in adults hospitalized with acute heart failure and cardiogenic shock. The main question is whether clinical findings, imaging results, and biomarkers, including sex-specific factors, are associated with the risk of death within 30 days. Participants will not receive an experimental treatment. Researchers will collect data from routine care, collect additional blood and urine samples for biobanking, and follow participants after hospital discharge

03

Conditions studied

  • Cardiogenic Shock
  • Acute Heart Failure (AHF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adult patients hospitalized at participating study sites with acute heart failure and cardiogenic shock (SCAI stages B-E).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalized with acute heart failure SCAI stage B - E.

Exclusion criteria

Exclusion Criteria:

  • Not capable of providing due to reasons not attributable to cardiogenic shock
  • Cardiogenic shock following cardiothoracic surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Arm 1
06

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: 30 days

Secondary outcomes

  1. Mortality

    Time frame: 6 and 12 months

  2. Rehospitalization for heart failure

    Time frame: From hospital discharge until 12 months

  3. Rehospitalization for cardiac reasons (non-elective)

    Time frame: From hospital discharge until 12 months

Other outcomes

  1. Bleeding ≥ SHARC 3a

    Time frame: Index hospitalization

  2. Functional capacity (physical)

    Six-minute walk test

    Time frame: At 6 months follow up

  3. Functional capacity (cognitive)

    MOCA

    Time frame: At 6 months follow up

  4. Functional capacity

    KCCQ

    Time frame: At 6 months follow up

  5. Quality of life measure

    PHQ-2

    Time frame: At 6 months follow up

  6. Quality of life measure

    EQ-5D-5L

    Time frame: At 6 months follow up

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 35 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 7, 2026
StartActual
Aug 7, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07515508
Lead sponsor
University Heart Center Freiburg - Bad Krozingen
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Aug 7, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Lucas Bacmeister, MD
Contact
lucas.bacmeister@uniklinik-freiburg.de
004976127034010

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion